More than 40 women representing HIV prevention advocates, reproductive health service providers, and women living with HIV from Kenya, South Africa, Rwanda, Uganda and Zimbabwe met to review and discuss the existing data on hormonal contraceptive use and HIV risk.
African Women’s Civil Society Consultation on HIV Risk and Hormonal Contraceptives
AIDS Vaccine Science for Busy Advocates – Current AIDS Vaccine R&D Pipeline
One-pager reviewing what we’ve learned from previous efficacy trials, the product pipeline and where we are today and future directions toward finding a vaccine that works.
Microbicides for HIV Prevention: An introductory factsheet
This introductory 2-page document defines microbicides and reviews the state of research on some leading candidates.
Good Participatory Practice: Guidelines for biomedical HIV prevention trials second edition (Thai)
The Good Participatory Practice (GPP) guidelines offer trial funders, sponsors and implementers systematic guidance on how to engage stakeholders throughout the research lifecycle of HIV Prevention Trials.
This second edition of the guidelines, published in 2011, contains three sections: The Importance of Good Participatory Practice, Guiding Principles of GPP in Biomedical HIV Prevention Trials and Good Participatory Practices in Biomedical HIV Prevention Trials. The sections provide context, foundational principles and key practices.
Good Participatory Practice: Guidelines for biomedical HIV prevention trials second edition (Russian)
The Good Participatory Practice (GPP) guidelines offer trial funders, sponsors and implementers systematic guidance on how to engage stakeholders throughout the research lifecycle of HIV Prevention Trials.
This second edition of the guidelines, published in 2011, contains three sections: The Importance of Good Participatory Practice, Guiding Principles of GPP in Biomedical HIV Prevention Trials and Good Participatory Practices in Biomedical HIV Prevention Trials. The sections provide context, foundational principles and key practices.
Good Participatory Practice: Guidelines for biomedical HIV prevention trials second edition (Portuguese)
The Good Participatory Practice (GPP) guidelines offer trial funders, sponsors and implementers systematic guidance on how to engage stakeholders throughout the research lifecycle of HIV Prevention Trials.
This second edition of the guidelines, published in 2011, contains three sections: The Importance of Good Participatory Practice, Guiding Principles of GPP in Biomedical HIV Prevention Trials and Good Participatory Practices in Biomedical HIV Prevention Trials. The sections provide context, foundational principles and key practices.
Women and HIV Prevention Research: Designing, testing and marketing products to improve adherence
The fourth webinar in AVAC’s Research & Reality series, a year-long dialogue about prevention research and advocacy, this webinar provided a forum to learn about and discuss key issues around women and the HIV prevention agenda, including challenges around marketing of and adherence to new prevention options. Click for speaker details, slides and audio.
Community Stakeholder Checklist
The Community Stakeholder Checklist is a set of questions that can be used by community stakeholders to evaluate a research team’s compliance with the Good Participatory Practice guidelines. The checklist can be used as a starting point for dialogue with a research team, a way to share experiences with other stakeholders or as an assessment tool.
Capitalizing on Scientific Progress: Investment in HIV Prevention R&D in 2010
This annual accounting of funding for biomedical HIV prevention research tracks trends and identifies gaps in investment. The 2011 report describes the funding environment in the wake of a number of the findings of efficacy in the RV144, CAPRISA, iPrEx and HPTN 025 trials and calls for sustained funding to build on these results.
Px Wire January-March 2012, Vol. 5, No. 1
Px Wire is AVAC’s quarterly update covering the latest in the field of biomedical HIV prevention research, implementation and advocacy. This issue identifies ten key outcomes to pursue in order to make progress in beginning to end the AIDS epidemic. This issue also covers Gilead Science’s submission to the FDA for a label change for TDF/FTC (brand name Truvada); the closure of the 1% tenofovir gel arm of the VOICE trial; new trials launched this quarter; the first meeting of Project ARM (Africa for Rectal Microbicides).